StockNews.AI
NTLA
StockNews.AI
2 days

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1. Intellia awarded 65,200 RSUs to six new employees. 2. The RSUs will vest over three years, conditional on employment. 3. The grants are part of Intellia’s 2024 Inducement Plan. 4. The plan aims to attract and retain talent in gene editing. 5. Intellia's efforts continue to strengthen its CRISPR platform.

4m saved
Insight
Article

FAQ

Why Bullish?

Attracting key talent through inducement grants suggests growth potential and strategic focus, similar to other biotech firms that benefitted from talent acquisition strategies.

How important is it?

Inducement grants can drive innovation and efficiency in talent-centric sectors, reflecting positively on the company’s market position and strategic direction.

Why Long Term?

The investments in talent reflect confidence in future projects, which may enhance long-term value as they lead product development in gene editing.

Related Companies

CRSPEDITSGMO
October 03, 2025 16:01 ET  | Source: Intellia Therapeutics, Inc. CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 65,200 shares of Intellia’s common stock, with one-third of such RSUs vesting on October 1, 2026, 2027 and 2028. All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates. All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4). About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx. Intellia Contacts: Investors:Jason FredetteVice President, Investor Relations and Corporate Communicationsjason.fredette@intelliatx.com Media:Matt CrensonTen Bridge Communicationsmedia@intelliatx.commcrenson@tenbridgecommunications.com

Related News